Mette Kristine Agger

Managing Partner, Lundbeckfonden Ventures

Mette Kirstine has a broad international experience within biotech / life science covering business development and licensing, management and financing. She was previously co-founder and CEO of 7TM Pharma A/S and prior to this, Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She started her carrier as Patent Agent and has over the years co-founded several biotech companies. Mette has been appointed to numerous board positions both in private and public companies. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA.

Giovanni Ferrara

Venture Partner, Novartis Ventures, Cambridge

Giovanni Ferrara joined Novartis Venture Funds in 2011. Prior, he spent three years as a consultant to leading west coast venture capital firms and portfolio companies. Most recently, he was consulting Chief Business Officer to Sorbent Therapeutics, where he raised $58M in two financings and led a refocusing of the company’s clinical activities and business development strategy. Previously, he was Managing Director and General Partner at Burrill& Company, and began his venture capital career at GeneChem Management, where he invested and also held operating positions in portfolio companies, including CEO of Targanta Therapeutics (then PhageTech, Inc.). He began his career in healthcare as a pharmacist at a cancer treatment center researching experimental therapies. He received his MBA and MSc at McGill University.

Michael Ross

Managing Partner, SV Life Sciences

Dr. Michael Ross joined SVLS as a Venture Partner in 2001, became a Managing Partner in 2002 and is based in San Francisco. Michael serves on the Thayer School of Engineering (Dartmouth College). He has also served on the boards of Carta Proteomics, Epimmune, Genencor, MetaXen, and Xenova. Michael was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha -Roche), Protropin® (hGH), Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. Michael then started Genentech's protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Michael was the Founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Novocell). Michael was also Managing Partner in Didyma, LLC, a biotechnology management consulting firm.Michael received his AB from Dartmouth College, his PhD in Chemistry at Caltech, and completed a Post Doctorate in Molecular Biology at Harvard.